EUVIMEDEUVIMED entdecken
Crossref

Macrolide and Ketolide Antibiotics Inhibit the Cytotoxic Effect of Trastuzumab Emtansine in HER2-Positive Breast Cancer Cells: Implication of a Potential Drug–ADC Interaction in Cancer Chemotherapy

Keisuke Kiyomiya, Ryuto Tomabechi, Naoki Saito, Kenta Watai, Tappei Takada, Yoshiyuki Shirasaka iD, Hisanao Kishimoto, Kei Higuchi, Katsuhisa Inoue iD

Molecular Pharmaceutics · 2023

DOI: 10.1021/acs.molpharmaceut.3c00490 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2023. Verfasst von Keisuke Kiyomiya und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biopharmaceutics, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, 1432-1 Horinouchi, Hachioji, Tokyo 192-0392, Japa…. Hauptthemen laut MEDLINE: Breast Neoplasms, Ketolides, Immunoconjugates, Maytansine. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 65 Literaturangaben. Gefördert von: Japan Society for the Promotion of Science, Japan Science and Technology Agency.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Macrolides are widely used for the long-term treatment of infections and chronic inflammatory diseases. The pharmacokinetic features of macrolides include extensive tissue distribution because of favorable membrane permeability and accumulation within lysosomes. Trastuzumab emtansine (T-DM1), a HER2-targeting antibody-drug conjugate (ADC), is catabolized in the lysosomes, where Lys-SMCC-DM1, a potent cytotoxic agent, is processed by proteinase degradation and subsequently released from the lysosomes to the cytoplasm through the lysosomal membrane transporter SLC46A3, resulting in an antitumor effect. We recently demonstrated that erythromycin and clarithromycin inhibit SLC46A3 and attenuate the cytotoxicity of T-DM1; however, the effect of other macrolides and ketolides has not been determined. In this study, we evaluated the effect of macrolide and ketolide antibiotics on T-DM1 cytotoxicity in a human breast cancer cell line, KPL-4. Macrolides used in the clinic, such as roxithromycin, azithromycin, and josamycin, as well as solithromycin, a ketolide under clinical development, significantly attenuated T-DM1 cytotoxicity in addition to erythromycin and clarithromycin. Of these, azithromycin was the most potent inhibitor of T-DM1 efficacy. These antibiotics significantly inhibited the transport function of SLC46A3 in a concentration-dependent manner. Moreover, these compounds extensively accumulated in the lysosomes at the levels estimated to be 0.41-13.6 mM when cells were incubated with them at a 2 μM concentration. The immunofluorescence staining of trastuzumab revealed that azithromycin and solithromycin inhibit the degradation of T-DM1 in the lysosomes. These results suggest that the attenuation of T-DM1 cytotoxicity by macrolide and ketolide antibiotics involves their lysosomal accumulation and results in their greater lysosomal concentrations to inhibit the SLC46A3 function and T-DM1 degradation. This suggests a potential drug-ADC interaction during cancer chemotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsKetolidesImmunoconjugatesMaytansineAntineoplastic AgentsHumansFemaleAdo-Trastuzumab EmtansineAzithromycinClarithromycinErb-b2 Receptor Tyrosine KinasesAntibodies, Monoclonal, HumanizedTrastuzumabLysosomesAnti-Bacterial AgentsTriazolesMacrolides

Stichwörter der Autor:innen

SLC46A3antibody−drug conjugatedrug−ADC interactionlysosomemacrolidetrastuzumab emtansine

Substanzen

Ado-Trastuzumab EmtansineKetolidesImmunoconjugatesAzithromycinClarithromycinMaytansineErb-b2 Receptor Tyrosine KinasesAntibodies, Monoclonal, HumanizedTrastuzumabAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Biopharmaceutics, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, 1432-1 Horinouchi, Hachioji, Tokyo 192-0392, Japan.
  • Laboratory of Pharmaceutics, Kitasato University School of Pharmacy, 5-9-1 Shirokane, Minato-ku, Tokyo 108-8641, Japan.
  • Department of Pharmacy, The University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-ku, Tokyo113-8655, Japan.
  • Faculty of Pharmacy, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kakuma-machi, Kanazawa 920-1192, Japan.

ORCID-Profile: Yoshiyuki Shirasaka, Katsuhisa Inoue

Förderung

  • Japan Society for the Promotion of Science
  • Japan Science and Technology Agency

Zitieren

APA

Kiyomiya, K., Tomabechi, R., Saito, N., Watai, K., Takada, T., Shirasaka, Y., Kishimoto, H., Higuchi, K., & Inoue, K. (2023). Macrolide and Ketolide Antibiotics Inhibit the Cytotoxic Effect of Trastuzumab Emtansine in HER2-Positive Breast Cancer Cells: Implication of a Potential Drug–ADC Interaction in Cancer Chemotherapy. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.3c00490

Vancouver

Kiyomiya K, Tomabechi R, Saito N, Watai K, Takada T, Shirasaka Y, et al. Macrolide and Ketolide Antibiotics Inhibit the Cytotoxic Effect of Trastuzumab Emtansine in HER2-Positive Breast Cancer Cells: Implication of a Potential Drug–ADC Interaction in Cancer Chemotherapy. Molecular Pharmaceutics. 2023. doi:10.1021/acs.molpharmaceut.3c00490

BibTeX
@article{Kiyomiya2023,
  author = {Kiyomiya, Keisuke and Tomabechi, Ryuto and Saito, Naoki and Watai, Kenta and Takada, Tappei and Shirasaka, Yoshiyuki and Kishimoto, Hisanao and Higuchi, Kei and Inoue, Katsuhisa},
  title = {Macrolide and Ketolide Antibiotics Inhibit the Cytotoxic Effect of Trastuzumab Emtansine in HER2-Positive Breast Cancer Cells: Implication of a Potential Drug–ADC Interaction in Cancer Chemotherapy},
  journal = {Molecular Pharmaceutics},
  year = {2023},
  doi = {10.1021/acs.molpharmaceut.3c00490}
}
Kostenlos starten →